STRATA Skin Sciences Appoints Medical Device Commercial Leader Erica Jordan as Chief Executive Officer
Rhea-AI Summary
STRATA Skin Sciences (SSKN) appointed medical device commercial leader Erica Jordan as Chief Executive Officer, effective July 12, 2026, as the company enters its next development phase focused on market leadership and continued revenue growth in excimer laser therapy for dermatologic conditions.
According to STRATA, Jordan brings extensive experience in expanding and transforming sales operations, scaling organizations, revitalizing revenue, and launching products and services across diverse markets. She previously served as Chief Commercial Officer at Revance Therapeutics and Metrex president at Envista Holdings, and has held leadership roles at Change Healthcare, Philips Healthcare, Fujifilm Medical, Siemens Medical Solutions, and GE Healthcare. Jordan plans to scale STRATA’s commercial organization to broaden provider and patient access to therapies supported by proven clinical outcomes, established reimbursement, and a capital-light partnership model for dermatology practices. Chairperson Dr. Uri Geiger highlighted her track record and thanked long-tenured CEO Dr. Dolev Rafaeli for building STRATA’s foundation.
Positive
- New CEO appointment effective July 12, 2026 brings extensive commercial leadership in medical devices and healthcare
- Track record in scaling sales and operations including revenue growth, market expansion, and commercial team transformation
- Senior leadership experience at Revance Therapeutics, Envista Holdings, Change Healthcare, Philips, Fujifilm, Siemens, and GE Healthcare
- Strategic focus on scaling STRATA’s commercial organization to expand provider and patient access to excimer laser therapies
Negative
- Leadership transition from long-tenured CEO Dolev Rafaeli introduces typical execution and continuity risks during a strategic shift
Market reaction after CEO leadership change: SSKN -9.09% in the Jul 28 session
In the Jul 28 session, SSKN declined 9.09%, reflecting a notable negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 18 | Clinical publication | Positive | +0.0% | Peer-reviewed trial reported higher response rates for XTRAC plus JAK inhibitors in pediatric vitiligo. |
| Feb 19 | Nasdaq delisting | Negative | +8.2% | Nasdaq suspension and planned SEC deregistration accompanied an $8 million year-end cash balance. |
| Feb 18 | Clinical access expansion | Positive | -40.0% | Johns Hopkins added STRATA's XTRAC excimer laser to dermatology clinical offerings. |
| Feb 17 | Clinical efficacy analysis | Positive | -8.3% | Meta-analysis reported substantial PASI improvements from 308 nm excimer laser therapy. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
SSKN's recent record showed divergence between favorable clinical or access-related announcements and subsequent price reactions.
Key Terms
excimer laser medical
cpt code regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
Medical device veteran poised to lead STRATA to market leadership and continued revenue growth as Company continues next development phase
HORSHAM, Pa., July 28, 2026 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (“STRATA” or the “Company”), a global leader in excimer laser therapy dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, has appointed industry veteran Erica Jordan as Chief Executive Officer, effective July 12, 2026.
STRATA chairperson Dr. Uri Geiger stated, “Erica has a proven record of expanding and transforming sales operations in large markets. We look forward to collaborating closely with Erica as she brings STRATA into its next era and translates the historical expanded CPT Code coverage into commercial success. I also want to thank Dr. Dolev Rafaeli for his long tenure as CEO and building the foundation of Strata Skin Sciences”
Erica Jordan is a strategic commercial leader with a focus on partnering with providers to enable care and improve business practices. She is well versed in revitalizing organizations by increasing revenue, scaling operations, expanding markets, transforming sales and commercial teams, and launching innovative products and services in diverse markets. She has demonstrated a long-standing commitment to cross-functional collaboration and meaningful customer engagement, excelling in aligning teams with shared goals and navigating matrix organizations to achieve corporate objectives.
"STRATA has what many companies spend years trying to build: proven clinical outcomes, established reimbursement, and a commercial partnership model that removes the capital barrier for dermatology practices," said Ms. Jordan. "My focus will be on scaling the commercial organization so that more practices — and ultimately more patients who are candidates for these therapies — have access to them."
Prior to joining STRATA, Ms. Jordan served as Chief Commercial Officer for Revance Therapeutics, spearheading sales, marketing (B2B and B2C), operations, corporate communications, investor relations, corporate strategy, and business excellence in domestic and international markets. Prior, she served as Metrex president at Envista Holdings (former Danaher Company). She has held leadership positions within the sales and marketing functions at leading organizations, including Change Healthcare (now part of Optum), Philips Healthcare, Fujifilm Medical, Siemens Medical Solutions, and GE Healthcare. She holds a Bachelor of Science degree in Marketing from the University of Wisconsin- Milwaukee.
About STRATA Skin Sciences, Inc.
STRATA Skin Sciences is a medical technology company dedicated to developing, commercializing, and marketing innovative products for the in-office treatment of various dermatologic conditions, such as psoriasis, vitiligo, and acne. Its products include the XTRAC® excimer laser, VTRAC® lamp systems, and the TheraClear®X Acne Therapy System. STRATA is proud to offer these exciting technologies in the U.S. through its unique Partnership Program. STRATA’s popular partnership approach includes a fee per treatment cost structure versus an equipment purchase, installation and use of the device, on-site training for practice personnel, service and maintenance of the equipment, dedicated account and customer service associates, and co-op advertising support to help raise awareness and promote the program within the practice.
Safe Harbor
This press release includes “forward-looking statements” within the meaning of the Securities Litigation Reform Act of 1995. These statements involve known and unknown risks and uncertainties that may cause actual results to differ materially from those expressed or implied by such statements. STRATA Skin Sciences undertakes no obligation to publicly update or revise any forward-looking statements.
Contact
STRATA Skin Sciences, Inc.
5 Walnut Grove Drive, Suite 140, Horsham, PA 19044
(215) 619-3200 | ir@strataskinsciences.com | strataskinsciences.com
